Lilly’s Retatrutide Cuts Up to 23% Weight in Type 2 Diabetes Trial
Lilly’s investigational retatrutide produced up to 23% weight loss in Type 2 diabetes over 80 weeks, The Lancet reports, raising the efficacy bar and enforcement risk for peptide suppliers.